Cancer and risk of COVID-19 through a general community survey

Lee, Karla A.; Ma, Wenjie; Sikavi, Daniel; Wolf, Jonathan; Steves, Claire J.; Spector, Tim D.; Chan, Andrew T.

doi:10.1101/2020.05.20.20103762

Cited by 7 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of the app has been valuable to document the presence of different types of COVID‐19 symptoms in the community 19–21 . However, data on cutaneous symptoms were only recently collected, and this hindered our ability to identify at which stage of the disease they appear and how long they last.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*

et al. 2021

View full text Add to dashboard Cite

Summary Background One of the challenging aspects of SARS‐CoV‐2 infection is its diverse multisystemic disease presentation. Objectives To evaluate the diagnostic value of cutaneous manifestations of SARS‐CoV‐2 infection and investigate their duration and timing in relation to other COVID‐19 symptoms. Methods We used data from 336 847 UK users of the COVID Symptom Study app to assess the diagnostic value of body rash or an acral rash in SARS‐CoV‐2 infection, and data from an independent online survey of 11 544 respondents to investigate skin‐specific symptoms and collect their photographs. Results Using data from the app, we show significant association between skin rashes and a positive swab test result (odds ratio 1·67, 95% confidence interval 1·42–1·97). Strikingly, among the respondents of the independent online survey, we found that 17% of SARS‐CoV‐2‐positive cases reported skin rashes as the first presentation, and 21% as the only clinical sign of COVID‐19. Together with the British Association of Dermatologists, we have compiled a catalogue of images of the most common skin manifestations of COVID‐19 from 400 individuals ( https://covidskinsigns.com ), which we have made publicly available to assist clinicians in recognition of this early clinical feature of COVID‐19. Conclusions Skin rashes cluster with other COVID‐19 symptoms, are predictive of a positive swab test, and occur in a significant number of cases, either alone or before other classical symptoms. Recognizing rashes is important in identifying new and earlier cases of COVID‐19.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*

et al. 2021

View full text Add to dashboard Cite

show abstract

“…On one hand, Paul et al recently reported that haematological cancers are not at increased risk of contracting COVID-19 and its prevalence is similar to that of general population, while on the other hand, He et al from China showed that patients suffering from cancers are at twofold increased risk of getting infected with SARS-CoV-2 as compared to the native population [ 14 ]. Similarly, a United Kingdom (UK) population-based study reported that cancer patients had 60% increased risk of COVID-19 especially with age > 65 years and male sex [ 20 ]. Investigators from China have shown that patients with cancer are prone to developing severe symptomatic disease with rapid progression as compared to general population (median 13 vs. 43 days; p < 0.001) [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India

et al. 2021

View full text Add to dashboard Cite

There is limited evidence on various clinical aspects of SARS-CoV-2 infection in patients with haematological cancers. The risk factors, prognosis, and outcome of patients with haematological cancers with coexistent COVID-19 need to be explored in different subsets of population. A single-institutional prospective observational study was conducted at a tertiary level medical institute in North India. The clinical details of the recruited patients having haematological malignancies and diagnosed with COVID-19 between 15 March 2020 and 31 May 2021 were prospectively collected through the electronic patient database system. The outcomes with respect to 28-day and 56-day mortality and the associated risk factors for prognostication were analysed. Of the 5750 hospital admissions (inpatient and day-care) during the study period, two hundred and forty-two patients (4.2%) were diagnosed with COVID-19. Acute leukaemia was the most common haematological malignancy, seen in 117 (48.3%) patients. Eighty-nine (36.8%) patients had moderate-to-severe COVID-19 while 153 (63.2%) patients presented with mild infection. The 28-day and 56-day mortality rates in our cohort were 13.3% and 19.8% respectively. Amongst the risk factors associated with poor outcome, the severity of COVID-19 (HR = 1.8, 95% CI 1.16–10.35; p = 0.04), presence of secondary infection (HR = 2.1, 95% CI 2.45–21.3; p = 0.023), and need for invasive mechanical ventilation (HR = 2.3, 95% CI 1.8–18.43; p = 0.01) were prognostically significant on multivariate log rank analysis. The risk of SARS-CoV-2 infection does not increase with haematological malignancies; however, the outcome remains poor in patients with severe COVID-19, requirement of invasive mechanical ventilation, and pre-existing bacterial/fungal infection at presentation.

show abstract

“…Studies in the US and Canada (CovidNearYou 10 , 11 ), UK (Covid Symptom Study 12 , 13 , also in US) and Israel (PredictCorona 14 ), have reported large cohorts of users drawn from the general population with a goal towards capturing information about COVID-19 along a variety of dimensions, from symptoms to behavior, and have demonstrated some ability to detect and predict the spread of disease 12 – 14 . This field has rapidly evolved since the beginning of the pandemic, with many analyses of these datasets focusing on COVID-19 diagnostics (i.e., symptoms, test results, medical background) 11 , care-seeking 15 , contact-tracing 16 , patient care 17 , effects on healthcare workers 18 , hospital attendance 19 , cancer 20 , primary care 21 , clinical symptoms 22 , and triage 23 . Here we perform a comprehensive analysis of a new source of COVID-19-related information spanning diagnostic and behavioral factors sampled from the general population during the beginning of the pandemic in the United States.…”

Section: Introductionmentioning

confidence: 99%

Population-scale longitudinal mapping of COVID-19 symptoms, behaviour and testing

et al. 2020

View full text Add to dashboard Cite

Despite the widespread implementation of public health measures, COVID-19 continues to spread in the United States. To facilitate an agile response to the pandemic, we developed How We Feel, a web and mobile application that collects longitudinal self-reported survey responses on health, behavior, and demographics. Here we report results from over 500,000 users in the United States from April 2, 2020 to May 12, 2020. We show that self-reported surveys can be used to build predictive models to identify likely COVID-19 positive individuals. We find evidence among our users for asymptomatic or presymptomatic presentation, show a variety of exposure, occupation, and demographic risk factors for COVID-19 beyond symptoms, reveal factors for which users have been SARS-CoV-2 PCR tested, and highlight the temporal dynamics of symptoms and self-isolation behavior. These results highlight the utility of collecting a diverse set of symptomatic, demographic, exposure, and behavioral self-reported data to fight the COVID-19 pandemic.

show abstract

Cancer and risk of COVID-19 through a general community survey

Cited by 7 publications

References 7 publications

Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*

Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*

Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India

Population-scale longitudinal mapping of COVID-19 symptoms, behaviour and testing

Contact Info

Product

Resources

About